DIRS.INFO The most relevant business & tech news

☆ JPMorgan says this new player in the GLP-1 market could rally 45%
▼ + stars: | 2024-09-11 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

JPMorgan thinks Viking Therapeutics could be the next big name in the GLP-1 boom. Investors are awaiting more details about the oral version, expected in early November, as a possible catalyst for the stock. VKTX YTD mountain Viking Therapeutics stock. Some patients who take these popular obesity drugs suffer nausea and gastrointensinal effects that force them to stop treatment. Oral drugs also tend to be cheaper and easier to manufacture.

Persons: GLP, Eli Lilly, Viking, Hardik Parikh, Parikh, Wegovy, Eli Lilly's Zepbound Organizations: JPMorgan, Viking, Therapeutics, Novo Nordisk, Investors, Viking Therapeutics

Several analysts raised their ratings and price targets on Starbucks a day after news that Chipotle CEO would take over at the coffee chain. Starbucks shares rallied on the news, while Chipotle shares fell. He also lowered his price target on shares to $685 from $750, which implies just 6% upside from Monday's close. Chipotle shares pulled back of 7% comes as decelerating trends and a sector rotation already impacted Chipotle's multiple. Since Niccol took the position of CEO in 2018, Chipotle shares surged more than 770%.

Persons: Bernstein, Fatima Boolani, Boolani, — Hakyung Kim, Eli Lilly Eli Lilly's, Berenberg, Lilly, Kerry Holford, " Holford, Morgan Stanley, Keith Weiss, Weiss, Hakyung Kim, Brian Niccol's, Danilo Gargiulo, Gargiulo, Niccol, Chipotle, Laxman Narasimhan, Brian Niccol, Baird, David Tarantino, Fred Imbert Organizations: CNBC, Citi, Palo Alto, Palo Alto Networks, pharma, Intuit, Starbucks, Deutsche Bank, SBUX Locations: Tuesday's

☆ Stocks making the biggest premarket moves: KeyCorp, Starbucks, JetBlue, Eli Lilly and more
▼ + stars: | 2024-08-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Check out the companies making the biggest moves in premarket trading: KeyCorp — Shares of the Cleveland-based regional bank jumped 18% after the announcement of a minority investment from The Bank of Nova Scotia. The deal gives Scotiabank 14.9% of KeyCorp's common stock for roughly $2.8 billion in cash. Eli Lilly — The pharma stock added 1.4% following an upgrade at Deutsche Bank to buy from hold. The bank cited Eli Lilly's recent earnings beat and called the stock a "low beta/high growth" unicorn. JetBlue Airways — Shares tumbled nearly 6% after the airline announced plans to offer $400 million of convertible senior notes due in 2029.

Persons: Eli Lilly, Eli Lilly's, Robinhood, Piper Sandler, Fred Imbert, Jesse Pound, Sarah Min, Pia Singh Organizations: The Bank of, Scotiabank, Starbucks, Street Journal, pharma, Deutsche Bank, JetBlue Airways, Hawaiian Electric Industries, Maui, Qualcomm, Wolfe Research, Apple Locations: Cleveland, The Bank of Nova Scotia

While keeping his outperform rating, Vijay Rakesh chopped $10 off his price target to $145. The Oreo maker should see above-average earnings growth, Jordan said, and the stock itself is a high-quality core holding. — Alex Harring 5:50 a.m.: UBS lays out earnings expectations for Nvidia UBS is remaining bullish on Nvidia heading into the artificial intelligence giant's earnings report. Analyst Timothy Arcuri reiterated his buy rating and $150 price target heading into earnings expected later this month. His price target of $23, up from $20, implies a gain of 28.3% over the next 12 months.

Persons: Piper Sandler, Vijay Rakesh, Rakesh, Alex Harring, Shaun Kelley, Kelley, — Alex Harring, Eli Lilly, Eli Lilly's, James Shin, Shin, Jefferies, Samad Samana, Samana, Goldman, Goldman Sachs, Mills, Leah Jordan, Jordan, Kraft Heinz, Timothy Arcuri, Arcuri, Patrick Moley, Morley, HOOD, Fred Imbert Organizations: CNBC, UBS, Mizuho, Micron, Seagate Technology, Western, Bank of America, Gaming, Consumer, Terre Haute, Kentucky Derby, Deutsche Bank, Par Technology, Jefferies, Conagra Brands, Hershey, Nvidia UBS, Nvidia Locations: Churchill, Northern, Northern Virginia, Kentucky, Robinhood

☆ Eli Lilly's earnings rally is not done yet — plus, why TJX has stayed resilient in the volatility
▼ + stars: | 2024-08-09 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. It's a big one for retail with earnings from Home Depot and Walmart and, more broadly, the Commerce Department's July retail sales report. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Cowen, TJ Maxx, we'll, Jim Cramer's, Jim Organizations: CNBC, Taiwan Semiconductor Manufacturing Company, Apple, Nvidia, Management, Home Depot, Walmart, Commerce, TJX, Reserve, Jim Cramer's Charitable Locations: Marshall's

☆ Eli Lilly's blowout quarter should quiet investor concerns about the stock
▼ + stars: | 2024-08-08 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. The report left little doubt that Eli Lilly's best days are ahead, driven by the growth of GLP-1s. It's really early" for Zepbound, Eli Lilly CEO David Ricks said in a CNBC interview Thursday. But the good news is Eli Lilly's multibillion dollar investments to expand manufacturing capacity are paying off.

Persons: Eli Lilly, Eli Lilly's, Zepbound, Jim Cramer, Lilly, David Ricks, It's, We're, Eli Lilly hasn't, Novo, spooked Lilly, Gordon Brooks, it's, Ricks, Brooks, Verzenio, —, didn't, Jim Cramer's, Jim, George Frey Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, CNBC, Food and Drug Administration, Viking Therapeutics, Novo Nordisk —, FDA, RTP, Bloomberg, Getty Locations: Eisai, U.S, GLP, Roche, it's, Indianapolis, North Carolina, Europe, Germany, Provo , Utah

☆ Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
▼ + stars: | 2024-08-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

Shares of Eli Lilly closed more than 9% higher on Thursday. That has forced Eli Lilly and its rival Novo Nordisk to invest heavily to boost manufacturing. "We just see unbelievable demand, and we're not even trying that hard to promote this drug," Eli Lilly CEO David Ricks told CNBC in an interview. Eli Lilly said sales were largely driven by higher demand for Mounjaro and Zepbound as production increases improved supply in the U.S. With a market cap of more than $730 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, Eli Lilly's, we're, David Ricks, Ricks, Zepbound, Mounjaro, Wegovy Organizations: U.S, Novo Nordisk, Food, CNBC, LSEG Locations: U.S, United States, Novo

☆ Eli Lilly's second quarter eases Zepbound pricing fears and suggests it's making headway in weight loss race
▼ + stars: | 2024-08-08 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Lilly's shares are up more than 7% on the news. LLY YTD mountain Eli Lilly shares year to date. The first followed positive reports from rivals that showed they were making progress in developing their own weight loss drugs . However, sales rose 59% for Mounjaro quarter over quarter and were up 140% for Zepbound as Lilly saw better pricing. Meanwhile, analysts see several events on the horizon that could further boost Lilly's shares in coming months.

Persons: Eli Lilly, Bansal, Lilly, Carter Gould, Lilly's headwinds, Novo's, Wells Fargo's Bansal, Evan David Seigerman, Chris Schott, Schott, Lilly's Organizations: Novo Nordisk, Wells, Barclays, Nordisk, BMO Capital Markets, Food and Drug Administration Locations: Wells Fargo, Lilly's, Wednesday's

☆ Eli Lilly reports earnings Thursday. Here's what Wall Street is watching
▼ + stars: | 2024-08-07 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Novo Nordisk shocked investors on Wednesday when its latest results fell short of Wall Street's expectations. While Eli Lilly's stock remains up about 32% year to date, concerns about increasing competition in the category have resulted in a nearly 16% decline for Lilly shares over the past month. Eli Lilly is making similar attempts with Zepbound, but its launch is at an earlier stage than Wegovy. Second-quarter sales of Ozempic, Novo's diabetes treatment, rose 4% from the first quarter, while Wegovy revenue grew 24% quarter over quarter. Barclays analyst Emily Field told clients in a research note that she would be a buyer of Novo Nordisk shares on the weakness.

Persons: Eli Lilly, Eli, Lilly, Wells, Mohit Bansal, Ozempic, Bansal, Emily Field, David Song, Song, Chris Schott, Schott Organizations: Novo Nordisk, LSEG, Lilly's, Management, Food and Drug Administration, Barclays, Tema, JPMorgan Locations: Wells Fargo, IQVIA, Amgen, MariTide, Novo, CagriSema

☆ Earnings playbook: Disney and this industrial giant are among companies slated to report this week
▼ + stars: | 2024-08-04 | by ( Fred Imbert | ) www.cnbc.com time to read: +4 min

More than 70 S & P 500 names are slated to report this week, including Disney and Caterpillar . Tuesday Uber Technologies is set to report earnings before the bell. This quarter: The ride-hailing giant is expected to report a 70% year-over-year increase in earnings, LSEG data shows. What history shows: Uber has beaten earnings expectations in six of the last seven quarters, according to data from Bespoke Investment Group. Wednesday Walt Disney is set to report earnings before the open.

Persons: Eli Lilly, Benjamin Black, Uber, Walt Disney, Wells, Steven Cahall, LLY, Eli Lilly's Organizations: Disney, Caterpillar . Pharmaceutical, behemoth, CNBC, Technologies, Investors, Autonomous Vehicle, Deutsche Bank, Investment, Caterpillar, JPMorgan Locations: California

☆ Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA says
▼ + stars: | 2024-08-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. All doses of Eli Lilly's highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the U.S. Food and Drug Administration's drug shortage database on Friday. The FDA's update comes one day after Eli Lilly CEO David Ricks told Bloomberg that the shortages of Mounjaro and Zepbound would end "very soon." A spokesperson for Eli Lilly did not immediately respond to CNBC's request for comment on the FDA's update on Friday. Meanwhile, the FDA said some doses of Novo Nordisk's weight loss drug Wegovy have limited supply.

Persons: Eli Lilly’s, Eli Lilly's, Zepbound, Eli Lilly, David Ricks Organizations: U.S . Food, Novo Nordisk, Bloomberg, FDA Locations: New York City, U.S

☆ Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Eli Lilly 's weight loss drug Zepbound showed benefits in patients with a common type of heart failure and obesity, according to late-stage trial data the company released Thursday. Eli Lilly said it plans to submit the results from the phase three trial to regulators in the U.S. and other agencies starting later this year. Zepbound also significantly improved heart failure symptoms and physical limitations, Eli Lilly said in a release. Eli Lilly will present the data at an upcoming medical meeting and submit it to a peer-reviewed journal.

Persons: Eli Lilly, Zepbound Organizations: Centers for Disease Control, Novo Nordisk, Drug Administration Locations: Brooklyn, New York, U.S

☆ Viking Therapeutics stock jumps 30% after drugmaker moves weight loss injection to late-stage trial
▼ + stars: | 2024-07-25 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Viking Therapeutics jumped more than 30% on Thursday after the biotech company a day earlier announced plans to advance its experimental weight loss injection into a late-stage trial earlier than expected. Viking is one of several small and large drugmakers hoping to compete in the space against Novo Nordisk and Eli Lilly , whose weight loss and diabetes GLP-1s have skyrocketed in demand over the last two years. During the call, Lian added that Viking expects to test VK2735 as a monthly injection in a future study. Viking Therapeutics' drug promotes weight loss by targeting a GLP-1 and another hormone called GIP. That pill caused 3.3% weight loss when compared to a placebo in an early-stage trial.

Persons: Eli Lilly, Viking, Brian Lian, Lian, Justin Zelin, Zelin, Eli Lilly's Zepbound Organizations: Viking Therapeutics, San, Novo Nordisk, Food and Drug Administration, FDA, Novo Nordisk's Wegovy Locations: San Diego

☆ Wegovy rival to be part of a suite of weight loss drugs, Roche CEO says following positive trial results
▼ + stars: | 2024-07-25 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Roche said Thursday that its Wegovy rival weight loss drugs will be part of a suite of medicines aimed at combatting the effects of obesity. CEO Thomas Schinecker welcomed positive early stage trial results from the firm's two weight loss drug candidates as showing "best in disease potential." "We do believe we have two next generation GLP-1/GIPs that have a best in disease potential," he said of the obesity drugs. GLP-1s, or glucagon-like peptide 1 agonists, are a group of drugs used to treat diabetes and obesity. They form the basis of weight loss drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Persons: Roche, Thomas Schinecker, Schinecker, CNBC's, Nordisk's Wegovy, Eli Lilly's Zepbound Organizations: Nordisk's

☆ How CrowdStrike's stumble could impact our cybersecurity stock Palo Alto
▼ + stars: | 2024-07-19 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Shares of Club holding Palo Alto Networks rose more than 1% Friday after an update from its cybersecurity rival CrowdStrike caused a widespread IT outage across the globe. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, CrowdStrike, Nikesh Arora, Jeff Marks, Jeff, Eli Lilly, Jim, Lilly, Roche, Eli Lilly's, Jim Cramer's Organizations: CNBC, Nasdaq, Dow Jones, Palo Alto Networks, Palo Alto, Novo Nordisk Locations: Danish

Here's a rapid-fire update on all 34 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Costco : While Costco gets nearly 7% of its sales from China, Jim said it's unlikely its business would be threatened by geopolitics given the company's popularity in the country. Constellation Brands : There's no doubt that the Modelo and Corona parent is a less attractive stock under Trump compared with Biden. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, Donald Trump, Abbott's, Reckitt Benckiser, we're, there's, it's, Biden, Dupont, Trump, Walt Disney, Nelson Peltz, Jim said, Estee Lauder, Eaton, Honeywell's, Washington that's, Eli Lilly, Roche, Eli Lilly's, Lilly, Sen, J.D, Vance of, Morgan Stanley, ChatGPT, chipmaker, Laxman Narasimhan, Stanley Black, Decker, rightsizing, Wells, Wynn, he's, Jim Cramer, Brendan McDermid Organizations: Jim Cramer's Charitable Trust, CNBC, Trump, Abbott Laboratories, AMD, Broadcom, VMWare, Costco, Coterra Energy, White, Bloomberg, Federal, Motors, Ford, GE Healthcare, Big Tech, Honeywell, Air Products, Linde, Meta, Microsoft, Investors, OpenAI, Republican, Palo Alto Networks, Palo, Procter & Gamble, Biden, Constellation Brands, Modelo, The, TJX, Wynn Resorts, Club, Jim Cramer's Charitable, Traders, New York Stock Exchange Locations: China, Dover, U.S, Washington, Vance of Ohio, Meta, Taiwan, Israel, Gaza, Corona, Wells Fargo, Macau, New York City

☆ Shares of this controversial health-care stock poised to break out to new high, according to the charts
▼ + stars: | 2024-07-16 | by ( Todd Gordon | ) www.cnbc.com time to read: +3 min

Shares of Hims & Hers (HIMS) , a digital consumer-facing health-care company, look poised to break out to a new all time high, according to the charts. HIMS announced in May a controversial weight loss injection product to compete with Lilly's Ozempic and Novo Nordisk's Wegovy. HIMS is not only marketing weight loss drugs, it has over one million subscribers using a wide variety of treatments. It's no secret that the total addressable market for weight loss drugs is gigantic. he volume was massive that day at over 70 million shares traded with average daily volume at round 18 million.

Persons: Howard Marks, HIMS, Lilly's, We've, Goldman Sachs, Eli Lilly's, Todd Gordon, Gordon Organizations: Capital Management, Novo Nordisk's Wegovy, Edge, Inside Edge, CNBC, NBC UNIVERSAL

☆ The best small- and midcap stocks to buy this summer, according to Oppenheimer
▼ + stars: | 2024-07-10 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

With the second half of the year underway, Oppenheimer is highlighting what it calls its top small- and midcap seasonal standout investment ideas. On the basis of price charts alone, Oppenheimer tapped midcap growth stocks as its top rotation idea from a technical perspective. Oppenheimer has a $20 price target on Zeta, implying 18% upside from Tuesday's close. In a note last month, RBC Capital Markets also rated Zeta outperform with a price target of $20. In this area, Oppenheimer likes Viking Therapeutics , reiterating the stock as one of its best ideas.

Persons: Oppenheimer, Russell, Brian Schwartz, Zeta, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Jay Olson, Freshpet Organizations: Oppenheimer, Zeta Global Holdings, Zeta, RBC Capital Markets, Novo Nordisk's, Viking Therapeutics, Therapeutics Locations: Zeta, Novo

☆ Stocks making the biggest moves midday: Nvidia, Corning, Helen of Troy, UiPath and more
▼ + stars: | 2024-07-09 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Helen of Troy — The housewares stock plummeted nearly 28%, hitting a new 52-week low during the session. The company posted an earnings miss for its first quarter of fiscal 2025 before the bell, earning 99 cents per share, excluding items. Lucid — The electric vehicle company's stock added nearly 1% after rallying about 8% in the previous session. Lucid jumped after the firm said it delivered 2,394 vehicles in the second quarter, marking a 70% year-over-year increase. Tesla — Shares of the electric vehicle company popped more than 4%.

Persons: Blackwell, Helen of Troy —, FactSet, UiPath, Lucid, Eli Lilly's Mounjaro, Eli Lilly, Morgan Stanley, Corning, Yun Li, Pia Singh, Sarah Min, Darla Mercado Organizations: Nvidia, UBS, BP — U.S, Novo Nordisk, Novo Nordisk's Ozempic, Sony, Paramount, National Amusements, Skydance Media, Apollo, CNBC Locations: Novo

☆ Companies besides tech can reach megacap status, Jim Cramer says
▼ + stars: | 2024-07-08 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

CNBC's Jim Cramer on Monday suggested that it is not just Big Tech that has the capacity to lead the market. Cramer highlighted Eli Lilly , a pharmaceutical giant whose stock hit a new high during Monday's session and is currently valued at about $870 billion. "These companies maintain their status through invention," Cramer said of huge names such as Amazon , Meta , Apple , Microsoft , Alphabet and Nvidia . The question is why other companies aren't doing the same things that Eli Lilly's doing to get in the winner's circle." Eli Lilly did not immediately respond to CNBC's request for comment.

Persons: CNBC's Jim Cramer, Cramer, Eli Lilly, Eli Lilly's, Eli Lilly's Alzheimer's, — Organizations: Big Tech, U.S . Food, Drug Administration, Apple, Microsoft, Nvidia Locations: U.S

☆ FDA approves a new Alzheimer's drug from Eli Lilly
▼ + stars: | 2024-07-03 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA approves a new Alzheimer's drug from Eli LillyEvan Seigerman, BMO Capital Markets senior research analyst, joins 'Squawk Box' to discuss the FDA's approval of Eli Lilly's Alzheimer's drug donanemab, how much revenue it could add to Elil LIlly's bottom line, and the details behind the newly approved drug.

Persons: Eli Lilly Evan Seigerman, Eli Lilly's Organizations: FDA, BMO Capital Markets

☆ Microsoft and Eli Lilly are among the most overbought stocks as the first half ends
▼ + stars: | 2024-06-28 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Shares of Microsoft registered a 14-day RSI reading of 74. MSFT YTD mountain MSFT YTD Shares of Eli Lilly are also overbought, with a 14-day RSI of 83, putting the drug manufacturer at the top of the list. FedEx is also overbought, with a 14-day RSI of 77. Among the oversold names, Walgreens Boots Alliance and Waters Corporation top the list with a 14-day RSI reading of 20, followed by Pool Corp . with an RSI reading of 22.

Persons: Friday's, Wall, Eli Lilly, Eli Lilly's Organizations: Dow Jones, Nasdaq, Nvidia, Microsoft, CNBC Pro, Union, FedEx, Walgreens Boots Alliance, Waters Corporation, Pool Corp, Walgreens

☆ Eli Lilly and Novo Nordisk are ahead in manufacturing but need time to meet demand, says Louise Chen
▼ + stars: | 2024-06-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly and Novo Nordisk are ahead in manufacturing but need time to meet demand, says Louise ChenLouise Chen, Cantor Fitzgerald analyst, joins CNBC's 'Squawk Box' to discuss Eli Lilly's surge over the past year, manufacturing, and more.

Persons: Eli Lilly, Louise Chen Louise Chen, Cantor Fitzgerald, Eli Lilly's Organizations: Novo Nordisk

☆ DuPont draws suitors for its water unit, plus what's driving Eli Lilly's bounce
▼ + stars: | 2024-06-25 | by ( Morgan Chittum | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Jim Cramer argued that the market's been too focused on the AI darling. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Jim, Eli Lilly, Novo Nordisk's Wegovy, Mounjaro, Ozempic, Jim Cramer's Organizations: CNBC, Nasdaq, Nvidia, DuPont, Bloomberg, Novo Nordisk's, Club Locations: China, LLY

☆ Eli Lilly's treatment for obesity and diabetes looks promising for another severe condition
▼ + stars: | 2024-06-24 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "This is what the bears should be most worried about, which is the [market] broadening out," Jim Cramer said Monday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Morgan Stanley, Wells Fargo, Eli Lilly, Jim, Jim Cramer's Organizations: CNBC, Dow, Nasdaq, Honeywell, Coterra Energy, Nvidia, Microsoft, U.S

Search resuls for: "Eli Lilly's"

25 mentions found